Gyre Q3 Revenue $32.9M, Swings to $2.5M Loss; F351 NMPA Decision Due by 1Q27
GYRE is trading near its 52-week low of $3.97 (1.0% above the low) on elevated volume (1.8× avg).
Summary
Gyre reported flat Q3 revenue of $32.9M but a $2.5M net loss versus $1.9M of income a year ago, with cash down to $98.8M. Full-year 2026 revenue guidance of $100.5M-$111.0M was affirmed, and the F351 NMPA decision is expected by year-end 2026 or 1Q27.
Key Events · Earnings and Guidance · GYRE
-
Q3 Revenue Flat, Profit Turns to Loss
Revenue of $32.9M versus $32.7M a year ago (+1%), while net loss was $2.5M versus $1.9M of net income, and basic EPS fell to $(0.04) from $0.01.
-
Nine-Month Loss Widens to $35.3M
Year-to-date net loss of $35.3M versus $4.6M of net income in 2025, driven by $6.9M of transaction costs and a $9.3M increase in external clinical research expense tied to the F351 NDA review.
-
Cash Falls to $98.8M
Cash, short-term deposits, short-term investments and long-term CDs totaled $98.8M at September 30, 2026, down $17.3M (15%) from $116.1M at December 31, 2025.
-
F351 Decision Due by 1Q27
The NMPA on-site inspection of manufacturing plants and clinical centers is complete; Gyre expects a decision by year-end 2026 or 1Q27 and a launch in 1H27 if approved.
Analysis · GYRE · Life Sciences
Revenue was essentially flat year over year at $32.9M, but the company swung from $1.9M of net income to a $2.5M net loss as operating expenses rose $3.2M. The nine-month picture is far worse: a $35.3M net loss versus $4.6M of income in 2025, with $6.9M of one-time transaction costs from the Cullgen deal and the terminated Pulmatrix merger plus a $9.3M jump in F351 review-related clinical spend. Cash and investments of $98.8M are down $17.3M since December, so the burn is real but the balance sheet still funds operations for now. With the stock trading near its 52-week low of $3.97, the F351 NMPA decision — expected by year-end 2026 or 1Q27, with launch in 1H27 — is the single event that can re-rate the equity; the on-site inspection is already complete, removing a key gating item.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GYRE was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.2M. The 52-week trading range was $3.97 to $9.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.